



Advances in Non-Intensive Therapies for AML: From CD47-Targeting to Combination Strategies and Beyond

References

1. Wacławiczek A, Leppä AM, Renders S, et al. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax. *Cancer Discov*. 2023 Jun 2;13(6):1408-1427. doi: 10.1158/2159-8290.CD-22-0939. PMID: 36892565; PMCID: PMC10236156.
2. Maiti A, DiNardo CD, Daver NG, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. *Blood Cancer J*. 2021 Feb 1;11(2):25. doi: 10.1038/s41408-021-00410-w. PMID: 33563904; PMCID: PMC7873265.
3. Short NJ, Daver N, Dinardo CD, et al. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. *J Clin Oncol*. 2024 May 1;42(13):1499-1508. doi: 10.1200/JCO.23.01911. Epub 2024 Jan 26. PMID: 38277619; PMCID: PMC11095865.
4. Lachowiec CA, Loghavi S, Zeng Z, et al. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. *Blood Cancer Discov*. 2023 Jul 5;4(4):276-293. doi: 10.1158/2643-3230.BCD-22-0205. PMID: 37102976; PMCID: PMC10320628.
5. Venugopal S, Takahashi K, Daver N, et al. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. *Blood Cancer J*. 2022 Jan 25;12(1):10. doi: 10.1038/s41408-021-00604-2. PMID: 35078972; PMCID: PMC8789767.
6. Wang ES, Heuser M, Montesinos P, et al. Patient Reported Outcomes in Patients with Newly Diagnosed FLT3^{mut} acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Laceywing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone. *Blood*. 2021;138(Supplement 1): 3058. doi: <https://doi.org/10.1182/blood-2021-144977>
7. Yilmaz M, Muftuoglu M, Kantarjian HM, et al. Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial. *JCO* 40, 7036-7036(2022). DOI:10.1200/JCO.2022.40.16_suppl.7036
8. Candoni A, Coppola G. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia. *Hematol Rep*. 2024 Apr 18;16(2):244-254. doi: 10.3390/hematolrep16020024. PMID: 38651453; PMCID: PMC11036224.
9. Liu QS, Welkie RL, Huang Y, et al. Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF). *Blood* 2023;142 (Supplement 1):5933. doi: <https://doi.org/10.1182/blood-2023-179609>



10. Lai C, Bhansali R, Kuo EJ, et al. Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician. *Am Soc Clin Oncol Educ*. Book 43, e390018(2023). DOI:10.1200/EDBK_390018
11. Santini V, Stahl M, Sallman D. *TP53* Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates. *Am Soc Clin Oncol Educ*. Book 44, e432650(2024). DOI:10.1200/EDBK_432650
12. Daver NG, Vyas P, Kambhampati S, et al. Tolerability and Efficacy of the Anticlust of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. *J Clin Oncol*. 2023 Nov 1;41(31):4893-4904. doi: 10.1200/JCO.22.02604. Epub 2023 Sep 13. PMID: 37703506; PMCID: PMC10617926.
13. Kieran D, Sahasrabudhe, Mims AS. Novel investigational approaches for high-risk genetic subsets of AML: *TP53*, *KMT2A*, *FLT3*. *Hematology Am Soc Hematol Educ Program*. 2022(1):15–22. doi: <https://doi.org/10.1182/hematology.2022000325>
14. Yang H, Xun Y, & You H. The landscape overview of CD47-based immunotherapy for hematological malignancies. *Biomark Res*. 2023;11:15. <https://doi.org/10.1186/s40364-023-00456-x>
15. Sallman DA, Al Malki MM, Asch AS, et al. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. *J Clin Oncol*. 2023 May 20;41(15):2815-2826. doi: 10.1200/JCO.22.01794. Epub 2023 Mar 8. PMID: 36888930; PMCID: PMC10414740.
16. Daver N, Vyas P, Chao M, et al. A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with *TP53*-Mutant Acute Myeloid Leukemia. *Blood*. 2021;138 (Supplement 1):3426. doi: <https://doi.org/10.1182/blood-2021-145208>
17. Daver NG, Liu K, Kuwahara SB, et al. AML-577 A Phase III, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy (ENHANCE-3). *Clinical Lymphoma Myeloma and Leukemia*. 2023;23(Supplement 1):S313-S314. ISSN 2152-2650. [https://doi.org/10.1016/S2152-2650\(23\)01083-2](https://doi.org/10.1016/S2152-2650(23)01083-2).
18. Gilead Statement on Discontinuation of Phase 3 ENHANCE-3 Study in AML. February 7, 2024. Accessed June 7, 2024 at: <https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-discontinuation-of-phase-3-enhance-3-study-in-aml>



19. Daver N, Stein AS, Bixby D, et al. Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts). *Blood*. 2023;142(Supplement 1):4278. doi: <https://doi.org/10.1182/blood-2023-173991>
20. Advani R, Flinn I, Popplewell L, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. *N Engl J Med*. 2018;379:1711-1721.
21. Chao MP, Takimoto CH, Feng DD, et al. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. *Front Oncol*. 2020 Jan 22;9:1380. doi: 10.3389/fonc.2019.01380. PMID: 32038992; PMCID: PMC6990910.
22. Guy DG, Uy GL. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. *Curr Hematol Malig Rep*. 2018 Dec;13(6):417-425. doi: 10.1007/s11899-018-0472-8. PMID: 30280288; PMCID: PMC6295344.
23. Clark MC, Stein A. CD33 directed bispecific antibodies in acute myeloid leukemia. *Best Practice & Research Clinical Haematology*. 2020. 33(4): 101224. ISSN 1521-6926. <https://doi.org/10.1016/j.beha.2020.101224>.
24. Key Statistics for Acute Myeloid Leukemia (AML); January 17, 2024. Accessed June 7, 2024 at: <https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html>
25. Jin X, Zhang M, Sun R, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. *J Hematol Oncol*. 2022 Jul 7;15(1):88. doi: 10.1186/s13045-022-01308-1. PMID: 35799191; PMCID: PMC9264641.
26. Liu F, Cao Y, Pinz K, et al. First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial. *Blood*. 2018;132 (Supplement 1):901. doi: <https://doi.org/10.1182/blood-2018-99-110579>
27. Zhang X , Lv H, Xiao X, et al. A Phase I Clinical Trial of CLL-1 CAR-T Cells for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in Adults. *Blood*. 2023;142 (Supplement 1):2106. doi: <https://doi.org/10.1182/blood-2023-180387>
28. Zhang H, Wang P, Li Z, et al. Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia. *Clin Cancer Res*. 2021 Jul 1;27(13):3549-3555. doi: 10.1158/1078-0432.CCR-20-4543. Epub 2021 Apr 8. PMID: 33832948.
29. Weisdorf D. How old is too old for a transplant? *Best Pract Res Clin Haematol*. 2021 Mar;34(1):101243. doi: 10.1016/j.beha.2021.101243. Epub 2021 Jan 12. PMID: 33762098; PMCID: PMC7994544.



30. Jain T, Litzow MR. Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. *Ther Adv Hematol*. 2020 Jan 20;11:2040620719899897. doi: 10.1177/2040620719899897. PMID: 32010436; PMCID: PMC6971963.
31. Issa GC, Zarka J, Sasaki K, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. *Blood Cancer J*. 2021 Sep 29;11(9):162. doi: 10.1038/s41408-021-00557-6. PMID: 34588432; PMCID: PMC8481264.

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Pfizer, Inc.